Intranasal injection of Botulinum toxin type A in treatment of allergic rhinitis.
Abdel-Hak, B., G., O., Alsaied, A. (2020). Intranasal injection of Botulinum toxin type A in treatment of allergic rhinitis.. EKB Journal Management System, 31(1), 323-329. doi: 10.21608/mjmr.2022.221544
Balegh , H. Abdel-Hak; Osama G.; Alaa N. Alsaied. "Intranasal injection of Botulinum toxin type A in treatment of allergic rhinitis.". EKB Journal Management System, 31, 1, 2020, 323-329. doi: 10.21608/mjmr.2022.221544
Abdel-Hak, B., G., O., Alsaied, A. (2020). 'Intranasal injection of Botulinum toxin type A in treatment of allergic rhinitis.', EKB Journal Management System, 31(1), pp. 323-329. doi: 10.21608/mjmr.2022.221544
Abdel-Hak, B., G., O., Alsaied, A. Intranasal injection of Botulinum toxin type A in treatment of allergic rhinitis.. EKB Journal Management System, 2020; 31(1): 323-329. doi: 10.21608/mjmr.2022.221544

Intranasal injection of Botulinum toxin type A in treatment of allergic rhinitis.

Minia Journal of Medical Research
Volume 31, Issue 1, January 2020, Page 323-329  XML PDF (502.86 K)
Document Type: Original Article
DOI: 10.21608/mjmr.2022.221544
View on SCiNiTO View on SCiNiTO
Authors
Balegh , H. Abdel-Hak; Osama G.; Alaa N. Alsaied
Department of Otolaryngology, fucalty of Medicine, Minya university, Egypt .
Abstract
Objectives: We tested the effects of BTA injections in septum ,middle and inferior turbinates, on 
patients who had AR for a minimum of three years and had been treated unsuccessfully with 
conventional medications. Method: The study was an interventional case-control single-blind 
randomized clinical trial . 20 male and female AR patients who were referred to the hospital of Minya 
university ,in 2019; aged 15-52 years were selected on the basis of inclusion and exclusion criteria. 
The subjects were randomly assigned to the intervention (n=10) or control group (n=10). The 
intervention group received BTA (45 IU/ml; medytox), by injection intranasally in septum , middle 
and inferior turbinates. The control group received normal saline. The groups were evaluated by the 
same examiner. post-tests (1,4, and 12 weeks) were performed according to the authors’ pre-designed
checklist, the validity and reliability of which was previously established. The symptoms scored from 
none (0) to severe (10) at the test points. The statistical analysis was conducted with SPSS-19, with a 
significance level of 0.05. Results: Based on ANOVA, there was a significant difference (P<0.05) in
symptomatic relief between the intervention and control groups. No marked adverse effects were 
observed during the study. Discussion: An intranasal injection of BTA, , may alleviate AR symptoms 
with no significant adverse effects.

Keywords
Botulinum Toxin type A(BTA); allergic rhinitis (AR)
Supplementary Files
Statistics
Article View: 67
PDF Download: 71